Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development_老虎社区_美港股上老虎

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Reuters2021-11-22

BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Shlee
·2021-11-23
Nice
回复
1
举报
Anneater
·2021-11-22
Oh
回复
1
举报
CPCat
·2021-11-22
Hmm.. will it result in BIDU price increase?
回复
1
举报
NeedMoneyPls
·2021-11-22
What happened to sinovac
回复
点赞
举报
Ermmmmmm
·2021-11-22
Weird with baidu
回复
1
举报
Big Bull
·2021-11-22
👍
回复
5
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-22 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171692239","market":"us","top_or_hot":-1,"title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development","media":"Reuters","content":"<div>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and ...\n\n<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/>Reuters</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and ...\n\n<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIDU","symbol_name":"百度","start_time":0,"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","article_id":"1171692239","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","pubTimestamp":1637582731,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"translate_title":"百度与赛诺菲合作，将其算法用于基因疫苗和治疗开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9},"content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":875892565,"gmtCreate":1637630280003,"gmtModify":1637630280003,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3573647345754035","idStr":"3573647345754035"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875892565","repostId":1171692239,"repostType":2,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875061998,"gmtCreate":1637589166148,"gmtModify":1637589185756,"author":{"id":"3581571807225162","authorId":"3581571807225162","name":"Anneater","avatar":"https://static.tigerbbs.com/dd99ef969b35027be1194d21c5482e54","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3581571807225162","idStr":"3581571807225162"},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875061998","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875032514,"gmtCreate":1637586170024,"gmtModify":1637586170230,"author":{"id":"3582520228861009","authorId":"3582520228861009","name":"CPCat","avatar":"https://static.tigerbbs.com/3bafaf3d39abfb78a4bedf785310721a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3582520228861009","idStr":"3582520228861009"},"htmlText":"Hmm.. will it result in BIDU price increase?","listText":"Hmm.. will it result in BIDU price increase?","text":"Hmm.. will it result in BIDU price increase?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875032514","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875038849,"gmtCreate":1637585775168,"gmtModify":1637585775281,"author":{"id":"3577168442576973","authorId":"3577168442576973","name":"NeedMoneyPls","avatar":"https://static.tigerbbs.com/ae9445a785e57d1d8607eb2ae0dde618","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3577168442576973","idStr":"3577168442576973"},"htmlText":"What happened to sinovac","listText":"What happened to sinovac","text":"What happened to sinovac","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875038849","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875098682,"gmtCreate":1637584594415,"gmtModify":1637584597529,"author":{"id":"4087557783698070","authorId":"4087557783698070","name":"Ermmmmmm","avatar":"https://static.tigerbbs.com/b89bbeb73fe9212f0b5efc7185ae8a51","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087557783698070","idStr":"4087557783698070"},"htmlText":"Weird with baidu&nbsp;","listText":"Weird with baidu&nbsp;","text":"Weird with baidu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875098682","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":872777574,"gmtCreate":1637582901485,"gmtModify":1637582901485,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4094912318336650","idStr":"4094912318336650"},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872777574","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-22 20:05\n\n</h4>\n</header>\n<article>\nBEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.<blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more<blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.<blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.<blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.<blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.<blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.<blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.<blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.<blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","09888":"百度集团-SW","SNYNF":"Sanofi"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"BIDU":0.9,"09888":0.9,"SNYNF":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":29,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}